Evidence and evidence gaps of medical treatment of non-tumorous diseases of the head and neck

Abstract

Unfortunately, the treatment of numerous otolaryngological diseases often lacks an evidence base because appropriate studies are missing. Whereas sufficient high-quality trials exist for the specific immunotherapy of allergic rhinitis and in a limited measure also for the angiotensin-converting enzyme inhibitor induced angioedema, the evidence for Menière’s disease or for pharmacotherapy of postoperative laryngeal edema is rather poor. This contribution will discuss the trial situation and evidence of the respective diseases.

Keywords: Menière’s disease, specific immune therapy, post-surgery laryngeal edema, ACE inhibitor-induced angioedema

1 Postoperative laryngeal edema

Postoperative laryngeal edema may be the result of mechanical pressure caused by intubation pressure or after laryngeal interventions. Besides, also the duration of intubation is an important factor promoting the development of postoperative laryngeal edema. In the literature, postoperative laryngeal edema is also called post-intubation laryngeal edema. The postoperative laryngeal edema is a feared, possibly life-threatening complication. The risk increases especially after laryngeal surgeries and is well known to ENT specialists. In addition to extended protective intubation and temporary tracheostomy, the application of high-dose cortisone (250–1,000 mg methylprednisolone administered intravenously) is a common prophylactic measure. Now the evidence of this pharmacotherapy is not really clear and shows several gaps.

High-quality original papers about the efficacy of cortisone in this context are very rare. Mostly, those articles deal with retrospective evaluations of partly heterogenic patient populations. The oldest evaluation dates from 1987 and was performed in France [1]. In the context of a randomized trial, 276 patients were included. Half of them received 40 mg methylprednisolone. In this study, a nasotracheal tube was inserted in all patients. Postoperative laryngeal edema was observed in 6 patients. Four of those 6 patients were in the cortisone group. This means that even more patients developed postoperative laryngeal edema with cortisone than without treatment. With regard to this issue, also several Cochrane analyses were published. In 2000, a Cochrane analysis reported about the prophylactic application of intraoperative cortisone in children and adults [2]. In this context, all randomized and placebo-controlled trials were considered. The main criterion was the question of re-intubation after extubation. Another question was related to the symptom of stridor. Only 7 of 251 trials were qualitatively valuable to be included in the analysis. The patients belonged to different patient populations with regard to their basic disease. Statistically, only the postoperative stridor could be reduced with cortisone prophylaxis in children (n=216; RR=0.53; 95% CI 0.28, 0.97). In 3 trials with adults (n=1,047 patients), the cortisone prophylaxis could neither influence the postoperative stridor nor the re-intubation rate (RR=0.95; 95% CI 0.52, 1.72).

In a Chinese prospective randomized, double-blinded, and placebo-controlled trial with 40 patients, the stridor rate could be reduced after cortisone application, however, it had no impact on the re-intubation rate [3]. Another prospective, randomized, double-blinded, and placebo-controlled study of 64 children describes application of epinephrine and cortisone by inhalation directly before extubation. The result showed that epinephrine and cortisone do not have an impact on the development of laryngeal edema after extubation [4]. In 2009, another Cochrane analysis was performed on the basis of the analysis described above [5]. This time, 11 trials with 2,230 patients were considered as being qualitatively appropriate. Six studies were performed in adults, 2 in newborns, and 3 in children. The population of the newborns was so heterogenic and the application of cortisone was so various that no statistically significant conclusion could be drawn (RR 0.42; 95% CI 0.007 to 2.32). Even the studies with children had very heterogenic populations with partly known airway diseases. With regard to the children with airway abnormalities, the cortisone group showed less stridor (n=62), however, there was no effect in the children with regular airway constellations (n=153). In adults, the prophylactic cortisone application did not have an impact on the re-intubation rate (RR 0.48; 95% CI 0.19 to 1.22). The authors conclude that the prophylactic application of cortisone does not have any positive effect neither in newborns nor in children or adults.

Especially in ENT, there are no trials justifying for example the application of cortisone in laryngeal interventions. In
summary, the prophylactic application of cortisone to prevent postoperative laryngeal edema is not evidence-based.

2 Prophylactic medication of Menière’s disease

Clinically, Menière’s disease is characterized by recurrent, spontaneous vertigo attacks, fluctuating hearing loss, tinnitus, and pressure in the ear [6]. According to the current knowledge, an endolymphatic labyrinth hydrops causes those symptoms – either because of increased production or disturbed absorption [7]. The high endolymphatic pressure causes recurrent ruptures and leakage of Reissner’s membrane with mixing of low-potassium endolymph with potassium-rich perilymph [8]. The lifetime prevalence of Menière’s disease is around 0.5% [7]. Most commonly, the disease starts on one side, the frequency of attacks varies importantly. In the further course, 50% of the patients develop bilateral Menière’s disease [9]. This fact also explains why Menière’s disease is considered as the second most frequent origin of bilateral vestibulopathy.

Since the origins of endolymphatic hydrops – and thus Menière’s disease – are mostly unknown, targeted causal treatment is not possible. Pharmacotherapy aims at treating the vertigo attacks in the acute stage and furthermore to avoid attacks of Menière’s disease with vertigo and hearing loss [7].

The current therapy of Menière’s disease is based on two principles:

2.1 Treatment of acute attacks

Vertigo and nausea can be reduced by application of antivertigo agents as they are also administered for the treatment of other acute disorders of the labyrinth function, e.g. dimenhydrinate 100 mg as suppository [7].

2.2 Prophylactic treatment

The aim of prophylactic treatment is to reduce the endolymphatic hydrops. Despite the high prevalence of Menière’s disease and many clinical trials, there is no therapy up to now that is proven to be effective. The spectrum of recommendations reaches from salt-free nutrition, diuretic agents, transtympanic application of gentamicin (20–40 mg in intervals of several weeks until the symptoms improve) or betahistine up to surgical procedures [7].

Positive effects on the incidence of attacks were published for the transtympanic instillation of gentamicin [9] and high-dose, long-term application of betahistine dihydrochloride (3×48 mg per day for 12 months). The direct origin of Menière’s disease, i.e. the endolymphatic hydrops is often treated with betahistine. However, already in 2001 a systematic review (meta-analysis) of the Cochrane Collaboration revealed that there are not sufficient data to judge if betahistine has a real effect in the context of Menière’s disease [10], [11]. The skepticism regarding the application of betahistine has become more and more important since it is meanwhile possible to quantitatively measure the extension of the inner ear vessels filled with endolymph by means of magnet resonance imaging (MRI). In an according evaluation of 6 patients, betahistine showed no effect in none of the patients [10]; and a case study of a female patient over 2 years revealed the end of vertigo attacks but a deterioration of the hydrops and hearing capacity in both ears [10].

More recent studies postulate a clinical improvement of the symptoms of Menière attacks after application of high-dose, long-term betahistine therapy [12], [13], [14], [15]. A therapy recommendation is based on observations of 112 patients who received the medication either 3×16 mg/d or 3×24 mg/d or 3×48 mg/d for at least 12 months [15]. The higher dosage led to a significant reduction of the incidence of the attacks and was well tolerated. However, this trial was not randomized and not blinded. The results that were observed in this context have to be confirmed in a randomized and blinded study. In cases of severe and frequent attacks (more than 2 in 3 months), treatment with a low-dose loop diuretic (e.g. Furosemide) can be attempted [16]. Also in this context it must be emphasized that the effect has not been proven up to now [16]. Only two clinical studies have yet been published, while only one of those studies was double-blind and placebo-controlled. In this study, the diuretic therapy led to a reduction of the subjective vertigo attacks, but it had no effect on hearing loss and tinnitus [17], [18].

Circulation-enhancing by medication or compressed-air chambers are often applied for inner ear complaints such as sudden hearing loss or tinnitus, however, even in cases of confirmed diagnosis of Menière’s disease, those measures have no effect. Even other highly promoted procedures such as low-level laser therapy, where the auricle is irradiated with red light laser, must be questioned because laser light – that is said to have a positive effect on the sensory cells of the inner ear – physically does not reach this area.

During the last years, intratympanic injection of gentamicin and/or cortisone has been applied again and again in trials in different combinations. The objective of such treatments was to eliminate the vertigo attacks and to preserve the hearing capacity. According to a study performed in 2011, injection of gentamicin into the middle ear seems to reduce the vertigo attacks, however, the hearing loss cannot be avoided. Injection of cortisone has no impact on the occurrence of vertigo attacks [19].

3 Conclusion

Prophylactic pharmacotherapy of Menière’s disease is not sufficiently verified. The effect of certain drugs was not proven, it is only possible to reveal certain effect tendencies on isolated symptoms. The long-term treat-
Figure 1: ACE inhibitor-induced angioedema of the tongue and the larynx

4 Angioedema induced by angiotensin converting enzyme

4.1 Etiology and pathophysiology of angioedema

Angioedemas are edematous swellings of deeper tissue layers affecting the skin as well as the mucosa (Figure 1). Manifestations in the area of the airways may impair breathing and in rare cases they may even lead to suffocation [20]. Generally, angioedemas are classified into allergic (urticaria) and non-allergic angioedemas [21]. In contrast to allergic urticaria, it is typical for the non-allergic manifestation that skin reddening and in particular itching are missing. While histamine is the pathophysiological mediator of allergic urticaria, non-allergic angioedemas are mainly triggered by the effect of bradykinin as mediator (Figure 2).

This difference is crucial for a rationally sound therapy of the disease. One particular problem is chronic urticaria. Angioedemas that may develop in the course of the disease have an allergic genesis in only 10% of the cases [22], [23]. Hence, such angioedemas only rarely respond to anti-allergic standard therapies such as antihistamines and corticosteroids. Because of missing reddening of the skin or itching, it is often difficult to define the difference between angioedemas based on chronic urticaria and non-allergic angioedemas. Those difficulties in finding the correct diagnosis frequently result in an inadequate treatment of the patients. Bradykinin-induced angioedemas either result from increased bradykinin production or from inhibited bradykinin metabolism. Bradykinin is a nonapeptide that is physiologically produced within the kallikrein-kinin system. The history of the detection of the kallikrein-kinin system started more than 100 years ago when Abelouso and Bardier discovered the blood pressure lowering effect of urine [24]. Kinins are pharmacologically active peptides that are released by kallikrein from kininogens into body fluids and tissue. In contrast to this, the C1 inhibitor (C1-INH) works as endogenous kallikrein inhibitor and limits the synthesis of kinin. In addition to bradykinin, also kallidin and me-
thionyl-lysyl-bradykinin belong to the family of kinins. The last mentioned are transformed by amino-peptidases contained in the plasma and urine to bradykinin [25]. The kallikrein-kinin system is associated with the reninangiotensin-aldosterone system (RAAS) and partly antagonizes its effects. The functional linking between both systems is based on the non-specificity of the angiotensin-converting enzyme (ACE) that on the one hand produces angiotensin II and on the other hand degrades kinins such as bradykinin or substance P to inactive metabolites [26], [27]. Beside ACE, other proteases (aminopeptidase P, dipeptidylpeptidase IV, carboxypeptidase N) contribute to the metabolism of bradykinin. If those enzymes are inhibited in addition to ACE, further increase of the bradykinin concentration in the plasma and tissue must be expected [28], [29], [30].

4.2 Bradykinin receptors

Bradykinin receptors are G protein-coupled receptors ubiquitously located on the cell surface. Up to now, 2 receptor subtypes could be identified, i.e. the bradykinin receptor type 1 (BKR-1) and 2 (BKR-2). They have different pharmacological properties [31], [32], [33], [34], [35], [36], [37]. The human gene for BKR-2 was located on the chromosome 14q32 [38] whereas BKR-1 is found on chromosome 14q32.1-q32.2 [39]. The amino acid sequences of BKR-1 and BKR-2 only have a homology of 36% [37]. BKR-1 is synthesized de novo by many organs as reaction to tissue damage while BKR-2 is generally expressed constitutively [39], [40], [41].

4.3 Effects of bradykinin

In the 1980ies, the detection of different selective antagonists of BKR-1 and BKR-2 allowed important functional examinations of the role of kinins [34]. Recently, the development of C1-INH and BKR-2 transgenic mice led to important knowledge about the role of kinins in vivo [42], [43]. So for example the effect of bradykinin on the vascular permeability could be revealed by targeted inhibition of C1-INH [43]. Already earlier it was possible to show that bradykinin dilates peripheral and coronary arteries, that it may reduce arterial blood pressure in normotensive animals, and that it has anti-thrombogenic, anti-proliferative, and anti-fibrinogenic properties [41], [44], [45], [46], [47], [48]. According to the current knowledge, the cardio-vascular effect of bradykinin is mediated by activation of BKR-2 on endothelial cells which leads to a release of nitrogen monoxide (NO), prostaglandin PGI2, and the tissue-type plasminogen activator [49], [50]. It could also be shown that bradykinin is involved in the cardio-protective effect of “preconditioning” in myocardial ischemia or reperfusion injury [51]. Bradykinin can reduce the extent of infarction [52], [53] and limit the growth of cardiomyocytes [54], [55]. Furthermore, kinins can constrict the smooth bronchial muscles [56] which allows the conclusion that dry cough induced by ACE inhibitors is mediated by bradykinin and also substance P [57], [58]. Furthermore, the local accumulation of bradykinin may activate pro-inflammatory peptides and release local histamine possibly leading to hypersensitivity of the cough reflex [59]. Finally, it could be proven that bradykinin increases the release of insulin from the pancreatic B cell. This effect is mediated by the increase of intracellular calcium response on hyperglycemia [60], [61]. Bradykinin also increases the insulin-dependent transportation of glucose [62]. Further examinations revealed that locally released bradykinin increases the uptake and availability of glucose in target tissue independently from insulin secretion [63], [64]. Based on those findings it is most probable that the reduced metabolism of bradykinin contributes to the positive properties of the ACE inhibitor in patients suffering from cardiovascular diseases. This includes for example the reduction of diabetes-related consequential damage or the reduction of new cases of type-2 diabetes mellitus [65].
kallikrein, which accelerates the transformation of high molecular weight kininogen (HMWK) to bradykinin. In a family mostly women are affected; the intake of estrogen is a significantly precipitating factor. This circumstance may be explained by the fact that the coagulation factor XII is synthesized depending on estrogen. Accordingly, women who take estrogen-containing medication as for example the pill or who are pregnant are especially at risk because they have additionally increased factor XII serum concentrations beside the activating mutation. Very rarely, also male patients could be identified, however, their attacks occur less frequently and with lower intensity. The most frequent symptoms of the patients suffering from HAE type 3 are swellings of the face (93%) and the tongue (54%) as well as abdominal pain attacks (50%). Laryngeal (25%) and uvula edema (21%) are often observed [70]. In contrast to type 1 or 2, the quantitative and functional values of C1 esterase inhibitor are regular. However, mutations in exon 9 of the F12 gene can only be identified in part of the patients. So it can be expected that there are other genetic reasons for this subtype that are currently still unknown. Recently the first case of homozygous C1-INH lack with a mutation of c.1576 T>G was reported [69]. In mice, the targeted interruption of the C1-INH effect led to an increased vascular permeability that could be reversed by the treatment with human plasma pool C1-INH [43]. Other findings that were revealed in this transgenic murine population brought further convincing proofs for a significant involvement of BKR-2 in the pathogenesis of angioedema. So for example the increased vascular permeability could be reduced drastically by treatment with the BKR-2 antagonist icatibant (see below).

4.4.2 Triggering factors

Patients with HAE report about a multitude of factors that trigger angioedema attacks. Those are among others exposure to cold, mechanical trauma (e.g. tissue compres-

sion, sitting or standing for a longer time), certain food products (e.g. eggs, alcohol), infections, concomitant diseases, contact with pesticides or other chemicals, excitement, stress, and certain drugs such as ACE inhibitors and estrogens [67]. Those rather anecdotic reports, however, have never been evaluated systematically and seem to be influenced by individual patient characteristics. One exception in this context is the intake of estrogen-containing contraceptives and estrogen products for hormone replacement therapy. It could be shown that some female HAE patients react with an increased incidence of attacks when the serum estrogen is increased during the menstruation cycle, during pregnancy or because of contraceptives or postmenopausal hormone replacement therapy [70], [71]. Other researchers found similar cases in male and female patients who underwent antiandrogen therapy with cyproterone [72]. Even pharmaceutics inhibiting the metabolism of bradykinin may cause an increased incidence of attacks – hence ACE inhibitors are contraindicated in HAE patients [73], [74].

4.4.3 Iatrogenic bradykinin-induced angioedema

The most frequent reason for the occurrence of bradykinin-induced angioedema is the intake of pharmaceutics that lead to an inhibited metabolism of bradykinin. Those are not only ACE inhibitors such as enalapril but also AT1 blockers as losartan and the renin inhibitor aliskiren. The reduced metabolism of bradykinin induced by this group of drugs is the desired effect for therapy of cardiovascular diseases. However, it can be assumed that ACE inhibitors have a stronger inhibiting effect on bradykinin metabolism than other substance groups (Figure 3).
4.4.4 ACE inhibitor-induced angioedema

One characteristic of ACE inhibitor-induced angioedema is the regular manifestation in the area of the airways. Swellings in the head and neck region, especially pharynx and larynx, often require an inpatient treatment for several days and sometimes even intensive care is needed. The incidence of ACE inhibitor-induced angioedema varies according to the different examinations, probably because of ethnical differences. So the incidence of ACE inhibitor-induced angioedema in Caucasians amounted to 0.1–0.7% [20], [67], [68], [75], [76], whereas the susceptibility of colored Americans was much higher [77]. The current meta-analysis of the side effects of pharmaceutics for treatment of cardiovascular diseases in those patients revealed a relative risk for the manifestation of ACE inhibitor-induced angioedema that was three times higher than in white Americans [24]. Among the nearly 7 million patients treated with ACE inhibitors in Germany and an assumed rate of angioedema of 0.3–0.5%, around 20,000–35,000 cases have to be expected annually. This would mean a calculated incidence of 1:4,000, which means that ACE inhibitor-induced angioedema occurs much more frequently than HAE [78]. If other enzymes are inhibited beside ACE catalyzing the metabolism of bradykinin, an even higher bradykinin concentration must be expected [28], [29], [30]. This effect is obvious in the application of omapatrilat that inhibits neutral endopeptidase in addition to ACE. During the clinical testing phase, the comparison to the ACE inhibitor enalapril revealed a more than three times more frequent occurrence of angioedema (2.17 vs. 0.68%) so that finally this agent was not approved [59].

4.4.5 AT1 blocker-induced angioedema

Angioedema is more rarely caused by AT1 blocker than by ACE inhibitors [76], [78]. In the VALIANT trial, about 4,900 patients for each study arm were treated over 2 years with valsartan, captopril, or valsartan and captopril. While 0.2% of the patients of the valsartan group developed angioedema, 0.5% of the patients of each of the other two groups showed this side effect. However, in view of the mechanism of action it first seems to be surprising that also this angioedema is induced by bradykinin. Also the fact that the combined application of valsartan and captopril did not cause more angioedema than captopril alone might contradict to an involvement. But in the context of a recent study it could be shown that AT1 blockers increase the bradykinin level in hypertensive patients [79], [80]. The blood levels of angiotensin II increased under the treatment with AT1 blockers because those agents interrupt the physiological feedback mechanism that regulates the synthesis of angiotensin II via the release of renin [81]. At the same time, all AT type 1 receptors are blocked allowing the activation of more AT type 2 receptors by angiotensin II. In this context it seems to be important that the stimulation of AT type 2 receptors leads to an inhibition of the ACE activity via a still unknown mechanism [82]. So the increased bradykinin concentration in plasma observed by Campbell et al. after the application of AT1 blockers might be based on an inhibition of the bradykinin metabolism [80]. Based on earlier animal experiments, further evaluations are necessary to confirm the mentioned hypothesis [83]. Nonetheless, AT1 blockers should not be applied in patients who have already had an ACE inhibitor induced angioedema [84].

4.4.6 Renin-inhibitor-induced angioedema

Another pharmacological alternative to influence the renin-angiotensin-aldosterone synthesis is the application of the relatively new renin inhibitor aliskiren that is also admitted for the treatment of hypertonia. The inhibition of renin neither leads to a direct inhibition of ACE nor to an increased activation of AT type 2 receptors and thus probably not to an increased bradykinin concentration in the plasma. However, in the approval study, aliskiren did not turn out to be superior to ACEI or sartans [85], [86], [87], [88]. In the approval studies, patients suffering from mild or moderate hypertonia were included. In contrast to other antihypertensive agents, a reduction of the cardiovascular morbidity or mortality could not be proven for aliskiren [85], [86], [87], [88]. For patients having had angioedema induced by ACE inhibitors or sartans, aliskiren does not represent an alternative because this circumstance was classified as contraindication for therapy by the official authorities.

4.4.7 Acquired angioedema

Acquired angioedema (AAE) develop on the basis of non-genetic lack of C1-INH and mostly concern adults [87]. It can be induced for example by a severe basic disease such as malignant lymphoma. Patients with lympho proliferative diseases may develop angioedema that correlates with a reduced C1-INH plasma concentration and activity [89], [90]. In contrast to HAE with deficient C1-INH synthesis and/or activity, the AAE is characterized by the fact that a high number of idiotype-anti-idiotype immune complexes (autoantibodies) is present that consume C1q molecules and afterwards C1-INH [91]. Other diseases such as hepatocellular carcinoma and liver cirrhosis can be associated with reduced C1-INH plasma concentration, but in those cases angioedema has never been described. On the other hand, one case of a lymphoma-associated angioedema is known where the C1-INH plasma concentration was regular [92]. Recently a new C1-INH mutation was described that was associated with a significantly inhibited C1-INH secretion of the monocytes [92].
5 Therapy of acute ACE inhibitor-induced angioedema

The particular risk of angioedema of the head and neck is the obstruction of the airways leading to suffocation. With this regard it is necessary to clarify during each contact with the patient where exactly the angioedema is located, how severe the disease is, and especially if the airways are acutely at risk requiring immediate intervention. Generally, the following concepts are available for therapy of angioedema of the head and neck:

- Mechanical securing of the airways
- Supportive measures of therapy
- Symptomatic pharmacotherapy
- Causual pharmacotherapy

5.1 Mechanical securing of the airways

Mechanical securing of the airways must be considered when respiratory insufficiency is diagnosed:

- Inability to swallow (saliva runs out of the mouth)
- Inspiratory stridor
- Cyanosis

If one of these symptoms is observed, securing of the airways has to be immediately performed.

5.1.1 Types of mechanical securing

Depending on the location of the angioedema, the decision for a specific method must be taken (Table 1). Beside the above-mentioned symptoms, the degree of severity/the size of the angioedema is important for the technique. The classification of the laryngeal (Figure 4) and lingual angioedema (Figure 5) can be helpful to find the right decision. Because of the considerable tissue damage in the area of the upper airway and swallowing tract, the mechanical intervention may lead to a prolonged angioedema attack, sometimes even lasting for several days.

5.1.2 Supportive measures of therapy

In the context of angioedema in the area of the tongue and the oropharynx, sucking ice cubes may be helpful (vasoconstriction, decongestive effect). In cases of circulation problems, the application of infusions (sodium chloride/Ringer) is possible. The upright position of the upper part of the body is also useful.

5.1.3 Symptomatic pharmacotherapy

All agents that are effective for the therapy of angioedema attacks can be applied. The administration of other vasoconstricting agents such as epinephrine as inhalation/spray can also be applied (off-label use; dosage up to 8 mg per application). However, there are no trials regarding the efficacy. Thus, the supportive treatment of bradykinin induced angioedema with epinephrine is not evidence-based. In cases of pains, the application of analgesics as additional medication is possible.

5.1.4 Pharmacotherapy without efficacy proof

In cases of ACEI induced angioedema, no officially approved pharmacotherapy is available. Despite the missing approval (off-label use) ACEI induced angioedema were treated with cortisone (250–500 mg methylprednisolone) and antihistamines (clemastine 2 mg) in the past. There are neither studies nor case series supporting the efficacy of this treatment scheme. In one case series [93] the clinical course with cortisone and the time of complete healing of the edema were analyzed retrospectively. Under cortisone therapy, 3/47 patients had to undergo tracheostomy because of missing improvement, 2/47 were intubated, and 12/47 received a second cortisone application. The time of complete healing of the edema was 33 hours and was equal to placebo administration. A recently published double-blinded trial revealed an average of 27 hours until complete healing of the edema with cortisone and antihistamines and thus confirmed the missing effect of cortisone and antihistamines in the treatment of angioedema.

Conclusion: The application of cortisone and antihistamines in the context of angioedema is not evidence-based. Trials could not confirm a reliable effect [94].

5.1.5 Causal pharmacotherapy

Beside agents for circulation and respiration emergencies, specific causally effective drugs are available. Those are pharmaceutics that concern the pathophysiology and either avoid, stop, or attenuate the disease. In the context of bradykinin-induced angioedema, they either inhibit the bradykinin production or they impede its effect on its receptor.

The non-allergic, bradykinin-induced angioedema generally does not respond to antihistamines and corticoids in contrast to the allergic angioedema. A specific therapy of bradykinin-induced angioedema aims at avoiding the progression of the swelling to other levels of the head and neck area and to reduce the already existing symptoms as rapidly as possible.
Table 1: Applied methods for mechanical protection

| Location                                           | Measure                           |
|---------------------------------------------------|-----------------------------------|
| Lip, face (cheeks, periorbital region)             | No securing necessary            |
| Tongue, oral cavity                               | Nasal fiberoptic intubation       |
|                                                  | Nasopharyngeal airway             |
| Oropharynx (soft palate, uvula, posterior wall of | Nasopharyngeal airway             |
| the oropharynx, tonsillar bed)                    | Nasal fiberoptic intubation       |
|                                                  | Coniotomy/tracheostomy            |
| Base of tongue, hypopharynx, larynx (supra-larynx)| Nasal fiberoptic intubation       |
|                                                  | Oral intubation                   |
|                                                  | Coniotomy/tracheostomy            |

25% obstruction of the supra-larynx
- Few symptoms

LOC-1
- Monitoring

50% obstruction of the supra-larynx
- Moderate symptoms

LOC-2
- Monitoring

75% obstruction of the supra-larynx
- Severe symptoms

LOC-3
- Tracheostomy if needed

90% obstruction of the supra-larynx
- Acute threat to life

LOC-4
- Securing of the airways
- Nasal fiberoptic intubation
- Tracheostomy under local anesthesia

Figure 4: Classification of laryngeal edema

Lips, soft palate, and uvula are visible

Grade I

Soft palate and uvula are partly visible

Grade II

Small gap between the tongue and lips, the uvula is not visible

Grade III

The tongue completely fills the oral space

Grade IV

Hospitalization

Intensive Care Unit

Securing of the airways
Coniotomy/tracheostomy

Intubation/tracheostomy/coniotomy are required

Figure 5: Emergency management in the case of lingual angioedema

5.2 Icatibant

Since the majority of non-allergic angioedema is based on a pathological increase of the tissue hormone bradykinin, a reliable efficacy of the synthetic bradykinin B2 receptor antagonist icatibant (Firazyr™) can be expected. Icatibant acts as a bradykinin inhibitor by blocking the binding of native bradykinin to the bradykinin B2 receptor. Currently, icatibant is approved for symptomatic treatment of HAE angioedema in adults in the European Union. Icatibant (30 mg) is administered subcutaneously in the area of the abdomen, a first palliation of the symptoms is expected already after a median interval of about 45 minutes. Up to now, no systemic side effects have
been observed, there is only the description of a transitory erythema at the injection site. Since its approval, meanwhile dozens of patients suffering from ACE inhibitor-induced angioedema were treated successfully off-label. A total of 4 original papers were published on this topic. Three of those publications are case series encompassing 33 patients. The patients in these case series had received partly cortisone or they had been intubated. In all 3 case series, the successful treatment with icatibant was confirmed. The complete healing of the angioedema was achieved after an average of 4–5 hours. It took more than 33 hours to completely heal the angioedema with formerly applied therapy of cortisone and antihistamines [93]. The 4th original paper of our group is a double-blinded, two-arm, and randomized trial that was conducted as multicenter study. A total of 32 patients were screened and 30 of them were randomized afterwards. The patients received either icatibant and placebo or the standard therapy (cortisone and antihistamines) and placebo (Figure 6).

Half of the patients underwent acute therapy with 30 mg icatibant subcutaneously injected into the abdominal wall, the others were treated with the off-label standard therapy of 500 mg prednisolone (intravenous application) (Solu Decortin H, Merck) with 2 mg clemastine (Tavegil, Norvartis).

In order to analyze the pharmaceutics in an overall assessment, 3 rankings were performed: The patients assessed the intensity of 6 symptoms (pain, dyspnea, dysphagia, voice changes, foreign body sensation, and sense of pressure) on a visual analogue scale (VAS) from 0 (not present) to 10 (maximum intensity). This questionnaire was filled out before therapy and in several time intervals after application of the therapeutic medication. The examiner assessed the severity of the mentioned 6 symptoms based on a specific evaluation scale. Furthermore, the examiner described the severity of the angioedema at four different locations: lips/cheek, tongue, oropharynx, and hypopharynx/larynx ranking from 0 (no angioedema) to 4 (severe swelling). The primary endpoint was the time of complete healing from the angioedema.

**Figure 6: Study design of AMACE**
Based on those analysis, the interval starting at the time of injection of the study medication up to the complete regression of the symptoms was assessed that represented the primary endpoint of the trial. Also the onset of symptom relief was an important criterion. Additionally, a comparison was made of the numbers of patients of both groups that did not respond to the therapy. In such a case, the patients received an emergency treatment consisting of 30 mg icatibant with 500 mg prednisolone, regardless the group to which they belonged. The evaluation of this study shows that icatibant is clearly superior to current standard therapy with prednisolone and clemastine. Finally, all patients of both cohorts had a complete resolution of the edemas, but 3 patients of the standard therapy group had to undergo the mentioned emergency treatment because of primary therapy resistance, which never happened after icatibant therapy. Due to a complicated course, tracheostomy had to be performed in one patient of the prednisolone/clemastine group.

The median time of the icatibant cohort to complete resolution of the angioedema was 8 hours, which was 70% shorter than the control group with standard therapy – they needed 27.1 hours (p<0.002). Five patients of the icatibant group observed complete regression within 4 hours, which did not happen once in the prednisolone/clemastine group. Furthermore, the onset of symptom relief was significantly earlier: on the average the time until the symptoms improved was 2 hours after icatibant application in comparison to 11.7 hours after standard therapy (Table 2, Figure 7).

![Overview of results](image)

**Figure 7: Overview of the results of the AMACE study comparing icatibant (blue) and prednisolone/clemastine (red)**

| Outcome                                                                 | Icatibant (N=13) | Standard Therapy (N=14) | P-Value |
|------------------------------------------------------------------------|------------------|-------------------------|---------|
| Median (IQR) time to complete edema resolution (primary end point) – hr | 8.0 (3.0–16.0)   | 27.1 (20.3–48.0)        | 0.002   |
| Proportion of patients with complete edema resolution at 4 hr post-treatment – no. (%) | 5 (39)           | 0 (0)                   | 0.02    |
| Median (95% CI) time to onset of symptom relief (composite investigator-assessed symptom score) – hr | 2.0 (1.0–8.1)    | 11.7 (8.0–18.0)         | 0.03    |
| Median (95% CI) time to onset of symptom relief (composite patient VAS score) – hr | 2.0 (2.0–6.3)    | 7.9 (1.2–11.8)          | 0.036   |
| Median (95% CI) time to onset of symptom relief (composite investigator-assessed angioedema score) – hr | 2.0 (2.0–12.0)   | 12 (11.3–NE)            | 0.003   | 0.003 |

Even the side effects of both therapies were included in the context of the study. The intravenous application of prednisolone/clemastine only rarely led to reactions. Systemic symptoms, however, appeared in single cases of this cohort. One test person complained about symptoms of mild obstructive lung disease, another patient of the same group had increased glucose values, one patient described symptoms of fatigue. In the other group of patients, the local reaction after subcutaneous injection of icatibant played the most important role – 7 patients suffered from pain, in the control group there were only 2 patients after intravenous application. Other reactions at the injection site were reddening, swelling, and thermal
sensation; however, systemic reactions did not occur in this group. The study was recently published in the New England Journal of Medicine [94]. The producing company currently applies for approval for this indication. In the USA, another trial is conducted to enlarge the number of patients (NCT01919801). In Germany, icatibant is increasingly applied off-label in patients suffering from acute ACEI-induced angioedema as emergency treatment. According to the results, the treatment of ACEI-induced angioedema is evidence-based. Another result of this study is the proof that the standard therapy (cortisone and antihistamines) is clearly inferior to icatibant and thus also the application in cases of bradykinin-induced angioedema is not indicated. Since an angioedema shows spontaneous self-limitation after about 16 hours, the healing of the edema after 27 hours in the cortisone group is comparable to placebo.

6 C1 inhibitor (C1-INH)

Currently 2 human C1 inhibitor concentrates (Berinert® and Cinryze®) are available for the treatment of HAE patients. A third C1 inhibitor concentrate (Ruconest®) is gained from rabbit milk. The intravenous application of the C1-INH concentrate (Berinert P®) is approved for the acute treatment of HAE since many decades and is successfully applied. Off-label it is also used for AAE. Despite the infection risk associated with every blood product, the concentrate turned out to be safe. Cases of viral transmission are not known. The C1-INH concentrate is applied intravenously with a dosage of 20 IE/kg bodyweight. It is applied for acute therapy as well as for prophylaxis. In single cases, also patients with ACEI-induced angioedema were treated with C1-INH concentrates. Recently also a case series of ACEI angioedema was published describing treatment with 1,500 IE Berinert [95]. In the case series, the time of complete healing was 10 hours. In comparison to the treatment with cortisone (33 hours or 27 hours), the treatment with Berinert would be more effective. However, in total only few cases were published internationally [95], [96], [97].

Regarding the patho-mechanism, the effect of C1-INH concentrate in ACEI angioedema is not yet clearly defined. It can be assumed that the treatment with C1-INH reduces further bradykinin production as consequence of an enzyme imbalance. Bradykinin is metabolized by other enzymes such as aminopeptidase 4 and carboxypeptidase. The effect is probably slower than the direct inhibition of the bradykinin receptors by icatibant. A double-blind study for assessment of the efficacy in this indication is performed since 2013 (NCT01843530). Only after finalization and analysis of the results, reliable data may be retrieved. Thus, the treatment of ACEI angioedema with C1-INH is currently not sufficiently evidence-based (Table 3).

7 Conclusion

For angiotensin-converting-enzyme inhibitor-induced angioedema, the bradykinin B2 receptor inhibitor icatibant provides a pharmaceutical agent for the first time that is effective according to current studies. However, only few trials have been conducted with this question. The agent is not yet approved officially for this indication and if needed it has to be applied off-label in emergency cases. Corticosteroids and antihistamines do not seem to be effective and are not approved for this indication.

8 Allergen-specific immunotherapy (AIT) of respiratory allergies

8.1 Pathophysiology and effect mechanism of specific immunotherapy

In the context of AIT, allergen extracts are presented to the immune system as molecule mixture either via the subcutaneous tissue (SCIT = subcutaneous immunotherapy) or via the mucosa (SLIT = sublingual immunotherapy). Those allergen extracts diffuse first into the local tissue and are absorbed by the local cells and then transported to the local lymph nodes [98], [99]. The bases of AIT are
some modulations of the immune system with activation of IgG antibodies that block an allergen antibody-mediated immune response and activation of regulator T cells (Treg) that inhibit a B and T cell mediated immune response to the allergen. Besides, also a cytokine controlled inhibition of the local inflammatory reaction is induced [100], [101], [102], [103], [104].

8.2 Specific immunotherapy

The allergen-specific immunotherapy (AIT) is a causal immuno-modulating therapy of respiratory allergies. The application of allergen extracts activates specific blocking antibodies, tolerance inducing cells and messenger substances that inhibit further enhancement of the immune response caused by allergens, that block specific immune responses, and that reduce the inflammatory reactions in the tissue. Clinically, this leads to a reduction of the symptoms and a change of the course of the disease. Some recent developments have contributed to confirm the position of AIT in the treatment of respiratory allergies. The quality of the allergen extracts is always improved by increasing standardization [105]. Basic research led to further clarification of the pathophysiology of respiratory allergies and the mode of action of specific immunotherapy [106], [107]. The implementation and official approval of the sublingual immunotherapy (SLIT) beside subcutaneous immunotherapy (SCIT) also belongs to the important milestones of AIT [108]. A recently published S2k AWMF practical guideline summarizes the study situation on AIT and the efficacy of different agents [109].

Economically, allergic rhinitis and its subsequent diseases (such as bronchial asthma) cause enormous direct and indirect costs. Accordingly, therapeutic options, especially AIT, are assessed socio-economically based on cost-benefit-effectiveness analyses [110], [111]. In long-term evaluations, AIT is significantly more cost-effective in comparison to symptomatic pharmacotherapy in allergic rhinitis and allergic bronchial asthma [112].

Meta-analyses clearly confirm the effectiveness of SCIT and SLIT for certain allergens and age groups. Data of controlled studies differ in view of their quantity, their quality, and dosage schemes and require drug-specific assessment [113]. Allergen extracts for SCIT or SLIT cannot be compared because of their heterogenic composition and different measuring methods of the effective ingredients. For SCIT, non-modified allergens are applied as aqueous or physically coupled (semi-depot) extracts as well as chemically modified extracts (allergoids) as semi-depot extracts. The allergen extracts for SLIT are administered as aqueous solutions or pills [114].

It is recommended to assess the single pharmaceutics according to clearly defined criteria. On the website of the German Society of Allergology and Clinical Immunology (DGAKI, Deutsche Gesellschaft für Allergologie und Klinische Immunologie), tables can be found showing a drug-specific description of the AIT products available in Germany, Switzerland, and Austria (http://www.dgaki.de/leitlinien/s2k-Leitlinie-sit/) (Table 4, Table 5, Table 6, Table 7).

The tables list the trials and their assessment criteria for adults and children. The efficacy of SCIT in the context of pollen-associated allergic rhino-conjunctivitis in adults is very well proven by numerous studies. The efficacy of drugs for dust mite allergy is well proven by some studies. However, the trial situation for children regarding both types of allergies is comparably poor. The efficacy of SLIT in the treatment of allergic rhino-conjunctivitis caused by grass pollen in adults and children is very well confirmed and for tree pollen allergy it is well proven in adults. For dust mite allergy, new controlled trials with sometimes high patient populations confirm the efficacy of SLIT in adults. For patients with allergic rhino-conjunctivitis, SCIT or SLIT can be performed with pollen or mite allergen extracts. The efficacy of this therapy was confirmed by at least one double-blind placebo-controlled trial [114].

The efficacy of AIT has been confirmed by numerous meta-analysis with many trials [114]. Calderon et al. evaluated 33 clinical studies on AIT in patients suffering from grass pollen allergy who met the predefined criteria. Dretzke et al. published a meta-analysis in 2013 evaluating 28 trials on allergic rhinitis [114].

Regarding dust mite allergy, a systematic review article on the efficacy and tolerance of SCIT and SLIT was published in 2013 encompassing 44 trials [115].

9 Conclusion

In summary, those meta-analysis and review articles confirm a well-documented efficacy of AIT. Because of the heterogeneity of the studies and the difficulty of direct comparison, a general recommendation cannot be given. The efficacy of each pharmaceutical product must be confirmed by specific trials.

10 Outlook

On the one hand, the presented cases show that there are still diseases in ENT that are not treated in an evidence-based way because of missing studies. On the other hand, those cases also show how difficult it is to plan, finance, and finally conduct acknowledged high-quality trials. For planning and conducting such studies the cooperation with several university hospitals is required. Beside the motivation of single colleagues also the infrastructure and professional study centers must be provided. The new study center of the German ENT Society could be such a platform. I would like to encourage motivated colleagues to perform research especially in those fields where evidence gaps are obvious.
Table 4: Pharmaceutical products for AIT with the number of the specific studies and the status of approval (source: website of DGAKI, www.dgaki.de/Leitlinien/s2k-Leitlinie-sit/)

| Pharmaceutical products for allergen-specific immunotherapy | Number of trials for grass pollen (among those trials with children) | PEI approved | Number of trials for early blossoming plant (birch) pollen (among those trials with children) | PEI approved | Number of trials for dust mites (among those trials with children) | PEI approved |
|-------------------------------------------------------------|---------------------------------------------------------------|--------------|-----------------------------------------------|--------------|-----------------------------------------------|--------------|
| **Allergoid SCIT allergens**                                |                                                               |              |                                               |              |                                               |              |
| Acaroid® Allergopharma                                     |                                                               |              |                                               |              |                                               |              |
| Allergovert® Allergopharma                                 |                                                               |              |                                               |              |                                               |              |
| Clustoid® ROXALL                                          | 1992                                                          | 0            | 1992                                          |              |                                               |              |
| Depigoid® Leti/Novartis                                    | 1                                                             | 0            |                                               |              |                                               |              |
| Depiquick® Leti/Novartis                                   | 1                                                             | 0            |                                               |              |                                               |              |
| Pollinex quatro® Bencard                                   | 2                                                             | 1            |                                               |              |                                               |              |
| Purethral® HAL Allergie                                    | 0                                                             | 1993         | 1                                             | 1989         | 0                                             |              |
| Roxel® ROXALL                                             | 0                                                             | 0            |                                               | 1976         | 0                                             | 1995         |
| **Non-modified SCIT allergens**                            |                                                               |              |                                               |              |                                               |              |
| ALK depot SQ® ALK-Abelló                                    | 4 (1)                                                         | 1990         | 2                                             | 1990         | 0                                             | 1990         |
| ALK 7® ALK-Abelló                                          | 1994                                                          | 1            | 1997                                          |              |                                               |              |
| AVANZ® ALK-Abelló                                          | 0                                                             | 0            |                                               |              |                                               |              |
| Novo-Helisen® depot Allergopharma                          |                                                               |              |                                               |              |                                               |              |
| Tyro Miibe Bencard                                         |                                                               |              |                                               |              |                                               |              |
| **Allergoid SLIT allergens**                               |                                                               |              |                                               |              |                                               |              |
| LAIS® Lofarma                                              | 1                                                             | 0            |                                               | 0            |                                               |              |
| **Non-modified SLIT allergens**                            |                                                               |              |                                               |              |                                               |              |
| Grazax® ALK-Abelló                                         | 7 (3)                                                         | 2006         |                                               |              |                                               |              |
| Oralair® Stallergenes                                      | 4 (1)                                                         | 2008         |                                               |              |                                               |              |
| Oralvac® Compact                                          |                                                               |              |                                               |              |                                               |              |
| SLITone® ULTRAS                                          | 0                                                             | 0            |                                               | 0            |                                               | 0            |
| Stalaraf® Stallergenes                                     | 2                                                             | 2005         |                                               |              |                                               |              |
| Sublivac® FIX HAL Allergie                                 | 0                                                             | 0            |                                               | 0            |                                               | 0            |
| Sulgen® ROXALL                                             | 0                                                             | 0            |                                               | 0            |                                               | 0            |

* The criteria are based on those of the Paul Ehrlich Institute (PEI) of the year of approval, partly they differ from current requirements.
** In studies, single products show an effect that does not meet the listed requirements, however, contribute to clinical documentation.
*** Table is not recommended as base for decision for prescribability and reimbursability in the sense of positive or negative list.

- Product is not available in Germany with this allergen.
(year) Product is approved for Germany with this allergen (year).
- Product is not approved for Germany with this allergen.
Table 5: Studies with positive proof of efficacy for early blossoming plants (birch pollen) (source: website of DGAKI, www.dgaki.de/Leitlinien/s2k-Leitlinie-sit/)

| 8 | Studies with positive proof of efficacy – early blossoming plants/birch pollen 7-2015 | Approval(year) | Study of children | SMS vs. ES | Evaluated patients/Randomized patients | Evaluation procedure |
|---|---|---|---|---|---|---|
| 3 Allergoid SCIT allergens | 1 | Depigoid<sup>6</sup> Holby AS, Strand V, Robinson DS, Sager A, Rak S. Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2010; 40: 1062-1070 | | | SMS 45/61 | PP |
| 1 Pollinex quattro<sup>5</sup> Drachenberg KJ, Heinze M, Urban E. Kurzzeit-Immuntherapie mit Baumpollen-Allergoiden und dem Adjuvanz Monophosphoryl Lipid A. Ergebnisse einer randomisierten, doppelblinden, placebokontrollierten Multicenterstudie. Allergologie 2002; 25: 466-474 | | | | SMS 58/84 | PP |
| 1 Purethall<sup>5</sup> Cuypens JL, Bullens D, Kleinjans H, van der Werf J and the Purethal Birch Efficacy Study Group. Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects. Clin Exp Allergy 2009; 39: 1903-1909 | 1989 | | ES | 58/62 | PP* |

| 3 Non-modified SCIT allergens | 2 | ALK-depot SQ<sup>6</sup> Arvidsson MB, Löwhagen O, Rak S. Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 2002; 109: 777-793 | 1990 | ES | 46/49 | PP |
| 1 | ALK<sup>7</sup> Balda BR, Wolf H, Baumgarten C, Klimek L, Rasp G, Kunkel G, Müller S, Mann W, Hauswald B, Heep W, Przybilla B, Amon U, Bischoff R, Becher G, Hummel S, Frosh PJ, Ruster Meyer T, Jäger L, Brehtler R, Luger T, Schnitzer J. Tree pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens. Allergy 1998; 53: 740-748 | 1997 | ES | 61/111 | PP** |

| 0 Allergoid SLIT allergens | 2 | Non-modified SLIT allergens | 2 | Stalaral<sup>5</sup> Khinchi MS, Poulsen LK, Carat F, André C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergenspecific immunotherapy: a randomized, placebocontrolled, double-blind, double-dummy study. Allergy 2004; 59: 45-53 | 2005 | ES | 58/71 | PP |
| | | | | | FAS 500/574 | FAS |
(Continued)

Table 5: Studies with positive proof of efficacy for early blossoming plants (birch pollen) (source: website of DGAKI, www.dgaki.de/Leitlinien/s2k-Leitlinie-sit/)

1) In studies, single products show an effect that does not meet the listed requirements, however, contribute to clinical documentation.

2) The criteria are based on those of the Paul Ehrlich Institute (PEI) of the year of approval, partly they differ from current requirements.

* The primary endpoint was a combined SMS of eyes, nose, and lung and was not achieved. Without the values for the lung, the criteria are fulfilled.

** An FAS evaluation (N=105) was performed, too, that could not show an effect of at least 20% compared to placebo.

Scores:
SMS: The combined symptom medication score revealed an efficacy of 20% over placebo.
ES: Both single scores (symptom and medication score) confirmed an efficacy of 20% over placebo.

**Evaluation procedure:**
- **ITT:** strict intention-to-treat (ITT) evaluation, all randomized patients were evaluated.
- **FAS:** full analysis test, oriented at the ITT principle. All available data are included in the evaluation, except (according to ICH guideline):
  - Inclusion criteria are definitely not met
  - No medication intake
  - Not a single score of the patient is available
- **PP:** per protocol. Dropouts are allowed that are not included in the FAS criteria, such as for example: moving, pregnancy, non-compliance etc.

**Significance of the studies**
- Conservative (based on daily practice, corresponding to Consort)
- Potential bias in favor of the intervention
|   | Studies\(^1\) with positive proof of efficacy – grass pollen 7-2015 | Approval\(^2\) (year) | Study including children | SMS vs. ES | Evaluated patients/Randomized patients | Evaluation procedure |
|---|---------------------------------------------------------------|------------------------|-------------------------|-----------|-------------------------------------|---------------------|
|   | Table is not recommended as base for decision for prescribability and reimbursability in the sense of positive or negative list. |                       |                         |           |                                     |                     |
| 6 | **Allergoid SCIT allergens**                                  |                       |                         |           |                                     |                     |
| 1 | Allergovit                                                   | 1992                   | SMS                     | 143/154   | PP                                  |                     |
|   | Carrion CJ. For the Study Group: Kettner J, Doemer C, Cromwell O, Norkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-absorbed six-grass pollen allergoid. Allergy 2005; 60: 801-807 | | | | | |
| 1 | Clustoid\(^\oplus\)                                           |                       | SMS                     | 102/121   | PP                                  |                     |
|   | Klirnek L., Uhlig I, Mösges R, Rettig K, Pfaar O. A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster protocol. Allergy 2014; 69: 1629-1638 | | | | | |
| 1 | Depigoid\(^\oplus\)                                          |                       | ES                      | 53/53     | ITT\(^*\)                           |                     |
|   | Alvarez-Cuesta E, Arogonees-Gilzon E, Martín-Carcia C, Berges-Gimeno P, Gonzalez-Mancebo E, Cuesta-Herranz J. Immunotherapy with depigmented gularaldehyde-polymerized extracts: changes in quality of life. Clin Exp Allergy 2005; 35: 572-578 | | | | | |
| 1 | Depiquick\(^\oplus\)                                         |                       | SMS                     | 179/195   | FAS                                 |                     |
|   | Pfaar O., Urry Z, Robinson DS, Sager A, Richards D, Howrylowicz CM, Brättigam M, Klirnek L. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy 2012; 67: 272-279 | | | | | |
| 2 | Pollinex Quattro\(^\oplus\)                                  |                       | SMS                     | 124/141   | PP                                  |                     |
|   | Draachenberg KJ, Wheeler AW, Stübben P, Harak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001; 56: 498-505 | | | | | |
|   | Du Buske LM, Frew AJ, Harak F, Keith PK, Corrigan CJ, Aberer W, Holdich T, Fischer von Weikerthal-Draachenberg KJ. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 2011; 32: 239-247 | | | | | |
| 4 | **Non-modified SCIT allergens**                              |                       |                         |           |                                     |                     |
| 4 | ALK-depot SQ\(^\oplus\)                                     | 1990                   | ES                      | 28/30     | PP                                  |                     |
|   | Dolz I, Martinez-Cócer C, Bartolomé JM, Cimarra M. A doubleblind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996; 51: 489-500 | | | | | |
|   | Frew AJ, Powell RJ, Corrigan CJ, Durham SR; UK Immunotherapy Study Group. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117: 319-325 | | | | | |
|   | Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 2006; 117: 263-268 | | | | | |
|   | Yes                                                          | SMS                     | 35/39                   | PP                                  |                     |
|   | Vamey VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. Brit Med J 1991; 302: 265-269 | | | | | |
|   | ES                                                           | 35/40                   | PP                      |                     |                     |
| No. | Allergoid SLIT allergens | Bas: Evidence and evidence gaps of medical treatment of... |
|-----|-------------------------|-----------------------------------------------------|
| 1   | LAIS®                   | Bordignon V. Efficacia di una nuova immunoterapia per graminaceae ad assorbimento orale. Studio parallel eseguito per tre anni. G Ital Allergol Immunol Clin 1994; 4 : 153-159 |
| 11  | Non-modified SLIT allergens | **Table 6: Studies with positive proof of efficacy for grass allergies (source: website of DGAKI, www.dgaki.de/Leitlinien/s2k-Leitlinie-sit/)** |
| 2   | **Studies with positive proof of efficacy – grass pollen 7-2015**  | Table is not recommended as base for decision for prescribability and reimbursability in the sense of positive or negative list. |
|     | Approval² (year)  | Study including children | SMS vs. ES | Evaluated patients/Randomized patients | Evaluation procedure |
| 7   | Grazax®  | **Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablet in North American children and adolescents. J Allergy Clin Immunol 2011; 127: 64-71** |
|     | **Bufe A, Eberie, Franke-Beckmann E, Funck J, Kimming M, Klimek L, Knecht R, Stephan V, Thoistrup B, Weisshaar C, Kaiser F. Safety and efficacy in children of an SQ-standardized grass allergen table for sublingual immunotherapy. J Allergy Clin Immunol 2009: 123; 167-173** |
|     | Dahl R, Kapp A, Colombo G, de Monchy JGR, Rak S. Emminger W, Rivas MF, Ribel M, Durham SR. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118: 434-440 |
|     | Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006; 61: 185-190 |
|     | Durham SR, Yang WH, Pedersen MR, MSc-Pharm, Johansen N, MSc-Chem Eng, Rok S. Sublingual immunotherapy with once-daily grass allergen tablets. A randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117: 802-809 |
|     | Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011; 127: 72-80 |
|     | Maloney J, Bernstein DI, Nelson H, Creticos P, Hébert J, Noonan M, Skoner D, Zhou Y, Kour A, Nolte H. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7 243: a large randomized controlled trial. Ann Allergy Asthma Immunol 2014: 112: 146-153 |
| 4   | Oralair®  | **Didier A, Malling HJ, Worm M, Horak F, Jäger S, Montagut A, André C, de Beaumont O, Melac M. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007: 120: 1338-1345** |
|     | **Didier A, Worm M, Harak F, Sussman G, de Beaumont O, Le Gall M, Melac M, Malling HJ. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablet in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2011; 128: 559-566** |

| 22  | Studies with positive proof of efficacy – grass pollen 7-2015 |  |  |  |  |  |
|-----|---------------------------------------------------------------|-------------------------------------------------|----------------|----------------|----------------|
|     | Approval² (year)  | Study including children | SMS vs. ES | Evaluated patients/Randomized patients | Evaluation procedure |
| 1   |  | ES | Unknown/60 | Not reported |  |
| 7   |  | Yes | SMS | 307/345 | FAS |
| 22  |  | Yes | ES | 238*253 | FAS |
| 11  |  | ES | 568/634 | FAS |  |
| 22  |  | ES | 93/114 | PP |  |
| 22  |  | ES | 640/855 | PP*** |  |
| 22  |  | SMS | 391/439 | FAS |  |
| 22  |  | Yes (250/283) | SMS | 1301/1501 | FAS |
| 22  |  | ES | 569/628 | FAS |  |
| 22  |  | ES | 461/633 | FAS |  |
### Table 6: Studies with positive proof of efficacy for grass allergies (source: website of DGAKI, www.dgaki.de/Leitlinien/s2k-Leitlinie-sit/)

| Studies with positive proof of efficacy – grass pollen 7-2015 | Approval² (year) | Study including children | SMS vs. ES | Evaluated patients/Randomized patients | Evaluation procedure |
|---------------------------------------------------------------|------------------|--------------------------|------------|----------------------------------------|----------------------|
| Wahn U, Tabar A, Kuna P, Haiken S, Montagut A, de Beaumont O, Le Gall M, SUT Study Group. Efficacy and safety of 5-grass-pollen-sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009; 123: 160-166 | Yes | ES | 266/278 | FAS |
| Cax LS, Casale TB, Nayak AS, Bernstein DI, Cretticos PS, Ambrosine L, Melac M, Zeldin RK. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergenspecific serum IgE. J Allergy Clin Immunol 2012; 130: 1327-1334 | | SMS | 438/473 | FAS |

1) In studies, single products show an effect that does not meet the listed requirements, however, contribute to clinical documentation.

2) The criteria are based on those of the Paul Ehrlich Institute (PEI) of the year of approval, partly they differ from current requirements.

* The result of this study with a mixture of olive tree and timothy grass does not allow conclusions on the efficacy of a mono-product of timothy grass alone. Furthermore, it does not correspond to the draft of the EMA guideline stating that only homologous groups should be mixed in an allergen extract.

** An FAS evaluation (N=1028) was performed, too, that could not show an effect of at least 20% compared to placebo.

*** The result was achieved in a subgroup of patients who started medication at least 8 weeks prior to the season. The primary endpoint of the study was missed.

**Scores:**

**SMS:** The combined symptom medication score revealed an efficacy of 20% over placebo.

**ES:** Both single scores (symptom and medication score) confirmed an efficacy of 20% over placebo.

**Evaluation procedure:**

**ITT:** strict intention-to-treat (ITT) evaluation, all randomized patients were evaluated.

**FAS:** full analysis test, oriented at the ITT principle. All available data are included in the evaluation, except (according to ICH guideline):
- Inclusion criteria are definitely not met
- No medication intake
- Not a single score of the patient is available

**PP:** per protocol. Dropouts are allowed that are not included in the FAS criteria, such as for example: moving, pregnancy, non-compliance etc.

**Significance of the studies:**

Conservative (based on daily practice, corresponding to Consort)

Potential bias in favor of the intervention
Table 7: Studies with positive proof of efficacy for dust mite allergies (source: website of DGAKI, www.dgaki.de/Leitlinien/s2k-Leitlinie-sit/)

| 2 | Studies¹ with positive proof of efficacy – dust mite allergens 7-2015 | Approval² (year) | Study including children | SMS vs. ES | Evaluated patients/ Randomized patients | Evaluation procedure |
|---|---|---|---|---|---|---|
| 2 | Allergoid SCIT allergens | | | | |
| 2 | Depigoid⁵ | 2004 | | ES | 55/63 | PP |
| | Ameal A, Vega-Chicote JM, Fernández S, Miranda A, Carmona MJ, Rondón MC, Reina E, García-González JJ. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy 2005; 60: 1178-1180 | | | | |
| | Garcia-Robaina JC, Sánchez I, de la Tarre F, Fernández-Caladas E, Casanovas M. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol 2006; 118: 1026-1032 | | | ES | 64/64 | ITT |

0 Non-modified SCIT allergens

0 Allergoid SLIT allergens

0 Non-modified SLIT allergens

1) In studies, single products show an effect that does not meet the listed requirements, however, contribute to clinical documentation.

2) The criteria are based on those of the Paul Ehrlich Institute (PEI) of the year of approval, partly they differ from current requirements.

Scores:
- SMS: The combined symptom medication score revealed an efficacy of 20% over placebo.
- ES: Both single scores (symptom and medication score) confirmed an efficacy of 20% over placebo.

Evaluation procedure:
- ITT: strict intention-to-treat (ITT) evaluation, all randomized patients were evaluated.
- FAS: full analysis test, oriented at the ITT principle. All available data are included in the evaluation, except (according to ICH guideline):
  - Inclusion criteria are definitely not met
  - No medication intake
  - Not a single score of the patient is available
- PP: per protocol. Dropouts are allowed that are not included in the FAS criteria, such as for example: moving, pregnancy, non-compliance etc.

Significance of the studies
- Conservative (based on daily practice, corresponding to Consort)
- Potential bias in favor of the intervention

Notes

Competing interests

The author declares to have received research support by the companies Shire (Firazyr®) and Behring (Berinert®).

References

1. Gaussorgues P, Boyer F, Piperno D, Gérard M, Léger P, Robert D. Cédème laryngé après extubation. Les corticoïdes ont-ils un rôle dans sa prévention? [Laryngeal edema after extubation. Do corticosteroids play a role in its prevention?]. Presse Med. 1987 Sep;16(31):1531-2.

2. Markovitz BP, Randolph AG. Corticosteroids for the prevention and treatment of post-extubation stridor in neonates, children and adults. Cochrane Database Syst Rev. 2000;(2):CD000100. DOI: 10.1002/14651858.CD000100

3. Lee CH, Peng MJ, Wu CL. Dexamethasone to prevent postextubation airway obstruction in adults: a prospective, randomized, double-blind, placebo-controlled study. Crit Care. 2007;11(4):R72. DOI: 10.1186/cc5957

4. Cesar RG, de Carvalho WB. L-epinephrine and dexamethasone in postextubation airway obstruction: a prospective, randomized, double-blind placebo-controlled study. Int J Pediatr Otorhinolaryngol. 2009 Dec;73(12):1639-43. DOI: 10.1016/j.ijporl.2009.08.004
5. Khemani RG, Randolph A, Markovitz B. Corticosteroids for the prevention and treatment of post-extrusion steroid in neviars, children and adults. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD001000. DOI: 10.1002/14651858.CD001000.pub3

6. Neuhauser HK. Epidemiology of vertigo. Curr Opin Neurol. 2007 Feb;20(1):40-6. DOI: 10.1097/WCO.0b013e328013f432

7. Minor LB, Schessel DA, Carey JP. Ménière’s disease. Curr Opin Neurol. 2007 Feb;19(7):16-9.

8. Yeh TH, Herman P, Tsai MC, Tran Ba Huy P, Van den Abbeele T. A cationic nonselective stretch-activated channel in the Reissner’s membrane of the guinea pig cochlea. Am J Physiol. 1998 Mar;274(3 Pt 1):C566-76.

9. Takumida M, Kakigi A, Takeda T, Anniko M. Ménière’s disease: a long-term follow-up study of bilateral hearing levels. Acta Otolaryngol. 2006 Sep;126(9):921-5. DOI: 10.1080/0001648050053204

10. James A, Thorp M. Menière’s disease. Clin Evid. 2005 Dec;14:659-65.

11. James AL, Burton MJ. Betahistine for Menière’s disease or syndrome. Cochrane Database Syst Rev. 2001;(1):CD001873. DOI: 10.1002/14651858.CD001873

12. Dziadziola JK, Laurikainen EL, Rachel JD, Quirk WS. Betahistine for Ménière’s disease or inactivates bradykinin. Biochim Biophys Acta. 1970 Aug 21;214(2):374-4.

13. Lamm K, Arnold W. The effect of blood flow promoting drugs on cochlear blood flow, perilymphatic pO(2) and auditory function in the normal and noise-damaged hypoxic and ischemic guinea pig inner ear. Hear Res. 2000 Mar;141(1-2):199-219.

14. Laurikainen E, Miller JF, Pyykö K. Betahistine effects on cochlear blood flow: from the laboratory to the clinic. Acta Otolaryngol Suppl. 2000;544:5-7.

15. Strupp M, Hupert D, Frenzel C, Wagner J, Hahn A, Klinger VC, Mansmann U, Brandt T. Long-term prophylactic treatment of attacks of vertigo in Menière’s disease—comparison of a high with a low dosage of betahistine in an open trial. Acta Otolaryngol. 2008 May;128(5):520-4. DOI: 10.1080/00016480701724912

16. van Deelen GW, Huizing EH. Use of diuretic (Dyazide) in the treatment of Ménière’s disease. Otolaryngol Head Neck Surg. 2006 Jun;134(3):400-5.

17. Yetisir S, Kertmen M, Yildirim A. Vestibular diuresis in suspected Menière patients. Acta Otolaryngol Belg. 2004;58(2):119-23.

18. Thirwall AS, Kundu S. Diuretics for Ménière’s disease or syndrome. Cochrane Database Syst Rev. 2006 Jul 19(3):CD003599. DOI: 10.1002/14651858.CD003599.pub2

19. Casani AP, Piaggi P, Cerchiai N, Seccia V, Franceschini SS, Dallan I. Intratympanic treatment of intractable unilateral Meniere’s disease: gentamicin or dexamethasone? A randomized controlled trial. Otolaryngol Head Neck Surg. 2012 Mar;146(3):430-7. DOI: 10.1177/0194599811429432

20. Bas M, Hoffmann TK, Kojda G. Evaluation and management of angiodema of the head and neck. Curr Opin Otolaryngol Head Neck Surg. 2006 Jun;14(3):170-5. DOI: 10.1097/01.moo.0000193202.85837.7d

21. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. Nonallergic angioedema: role of bradykinin. Allergy. 2007 Aug;62(8):842-56. DOI: 10.1111/j.1398-9995.2007.01427.x

22. Kaplan AP, Geaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009 Jun;39(6):777-87. DOI: 10.1111/j.1365-2222.2009.03256.x

23. Maurer M, Grabbe J. Urticaria: its history-based diagnosis and etiologically oriented treatment. Dtsch Arztebl Int. 2008 Jun;105(25):458-65; quiz 465-6. DOI: 10.3238/arztebl.2008.0458

24. McDowell SE, Coleman JJ, Fener RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ. 2006 May;332(7551):1177-81. DOI: 10.1136/bmj.38603.528113.55

25. Sharma JN. Does kinin mediate the hypotensive action of angiotensin converting enzyme (ACE) inhibitors? Gen Pharmacol. 1990;21(4):451-7.

26. Yang HY, Erdős EG, Levin Y. Characterization of a dipeptide hydrodazole (kininase II: angiotensin I converting enzyme). J Pharmacol Exp Ther. 1971 Apr;171(1):291-300.

27. Yang HY, Erdős EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta. 1970 Aug 21;214(2):374-6.

28. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998 Jun 6;351(9117):1693-7. DOI: 10.1016/S0140-6736(97)90137-X

29. Adam A, Cugno M, Molinaro G, Perez M, Lepage Y, Agostoni A. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet. 2002 Jun 15;359(9323):2088-9. DOI: 10.1016/S0140-6736(02)69814-6

30. Lefebvre J, Murphy LJ, Hartert TV, Jiao Shan R, Simmons WH, Brown NJ. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension. 2002 Feb;39(2 Pt 2):460-4.

31. Vavrek RJ, Stewart JM. Competitive antagonists of bradykinin. Peptides. 1985 Mar-Apr;6(2):161-4.

32. Roberts RA. Bradykinin receptors: characterization, distribution and mechanisms of signal transduction. Prog Growth Factor Res. 1989;1(4):237-52.

33. Regoli D, Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1990;41(Suppl 6):S30-8.

34. Regoli D, Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1990 Mar;32(1):1-46.

35. Hess JF, Borkowski JA, Young GS, Strader CD, Ransom RW. Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem Pharmacol. 1992 Apr;15(1):260-8.

36. McEachern AE, Shelton ER, Bhakta S, Obernoire R, Bach C, Zuppan F, Fujisaki J, Aldrich RW, Jarnagin K. Expression cloning of a rat B2 bradykinin receptor. Proc Natl Acad Sci USA. 1991 Sep;88(17):7724-8.

37. Menke JG, Borkowski JA, Bienio KK, MacNeil T, Derrick AW, Schneek RA, arasom RW, Strader CD, Linemeyer DL, Hess JF. Expression cloning of a human B1 bradykinin receptor. J Biol Chem. 1994 Aug 26;269(34):21583-6.

38. Ma JK, Wang DZ, Ward DC, Chen L, Dessai T, Chao J, Chao L. Structure and chromosomal localization of the gene (BDKRB2) encoding human bradykinin B2 receptor. Genomics. 1994 Sep;23(2):362-9. DOI: 10.1006/geno.1994.1512

39. Chai KX, Ni A, Wang D, Ward DC, Chao J. genomic DNA sequence, expression, and chromosomal localization of the human B1 bradykinin receptor gene (BDKRB1). Genomics. 1996 Jan;31(1):51-7. DOI: 10.1006/geno.1996.0008

40. Regoli DC, Marceau F, Lavigne J. Induction of beta 1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide. Eur J Pharmacol. 1981 Apr 24;71(1):105-15.
56. Fuller RW, Dixon CM, Cuss FM, Barnes PJ. Bradykinin-induced bronchoconstriction in humans. Mode of action. Am Rev Respir Dis. 1987 Jan;135(1):176-80. DOI: 10.1164/arrd.1987.135.1.176

57. Tsukagoshi H, Sun J, Kwon O, Barnes PJ, Chung KF. Role of neutral endopeptidase in bronchial hyperresponsiveness to bradykinin induced by IL-1 beta. J Appl Physiol. 1995 Mar;78(3):921-7.

58. Muke S, Aoki S, Itoh S, Iwata T, Ueda H, Katagiri T. Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension. 2000 Jul;36(1):127-31.

59. Hulsman AR, Raatgeep HR, Saxena PR, Kerrebijn FK, de Jongte JC. Bradykinin-induced contraction of human peripheral airways mediated by both bradykinin beta 2 and thromboxane prostanoid receptors. Am J Respir Crit Care Med. 1994 Oct;150(4):1012-8. DOI: 10.1164/ajrccm.150.4.792J2430

60. Yang C, Hsu WH. Glucose-dependency of bradykinin-induced insulin secretion from the perfused rat pancreas. Regul Pept. 1997 Jul 23;71(1):23-8.

61. Damas J, Bourdon V, Lefebvre PJ. Insulin sensitivity, clearance and release in kininogen-deficient rats. Exp Physiol. 1999 May;84(3):549-57.

62. Duka I, Shenouda S, Johns C, Kintsurashvili E, Gavras I, Gavras H. Role of the B(2) receptor of bradykinin in insulin sensitivity. Hypertension. 2001 Dec;38(6):1355-60.

63. Rett K, Wickmayer M, Dietze GJ. Metabolic effects of kinins: historical and recent developments. J Cardiovasc Pharmacol. 1990;15 Suppl 6:557-9.

64. Kishi K, Muromoto N, Nakaya Y, Miyata I, Hagi A, Hayashi H, Ebina Y. Bradykinin directly triggers GLUT4 translocation via an insulin-independent pathway. Diabetes. 1998 Apr;47(4):550-8.

65. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 Jan 31;342(4):145-53. DOI: 10.1056/NEJM200001303420401

66. Göring HD, Bork K, Späth RJ, Bauer R, Ziemer A, Hintner H, Wüthrich B. Untersuchungen zum hereditären Angioödem im deutschsprachigen Raum [Hereditary angioedema in the German-speaking region]. Hautarzt. 1998 Feb;49(2):114-22.

67. Agostoni A, Aygören-Pürsün E, Binkley KE, Blanch A, Bork K, Bouillet L, Bucher C, Castaldo AJ, Cicardi M, Davis AE, DeCarolis Zanichelli A, Zingale L. Hereditary and acquired angioedema: A functional perspective. Nat Rev Drug Discov. 2004 Oct;3(10):845-52. DOI: 10.1038/nrd1522

68. Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol. 2005 Sep;53(3):373-88; quiz 389-92. DOI: 10.1016/j.jaad.2004.09.032

69. Blanch A, Roche O, Urrutia I, Gamboa P, Fontán G, López-Trascasa M. First case of homozygous C1 inhibitor deficiency. J Allergy Clin Immunol. 2005 Dec;116(6):1530-5. DOI: 10.1016/j.jaci.2006.07.035

70. Bork K, Fischer B, Dewald G. Recurrence episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am J Med. 2003 Mar;114(4):294-8.

71. Bouillet L, Bonard D, Drueot C, Duponchel C, Farkas H, Fay K, Fekte B, Fischer B, Fontana L, Füst G, Giacomelli R, Gröner A, Hack CE, Harmat G, Jakobsen J, Jürgensen M, Kaprio M, Karadi I, Kitzinger J, Kolár T, Kreuz W, Lakatos P, Longhurst HJ, Lopez-Trascasa M, Martinez-Saguer I, Monnier N, Nagy I, Németh E, Nielsen EW, Njuehn JH, O’Grady C, Pappalardo E, Penna V, Perricone C, Perricone R, Rauch U, Roche O, Rusieck E, Späth PJ, Szendei G, Takác F, Tordai A, Truedsson L, Varga L, Visy B, Williams K, Zanichelli A, Zingale L. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004 Sep;114(3 Suppl):S51-131. DOI: 10.1016/j.jaci.2004.06.047
88. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf B. Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Efficacy of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009 Feb;119(4):530-7. DOI: 10.1161/CIRCULATIONAHA.108.826214

89. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore). 1992 Jul;71(4):206-15.

90. Cicardi M, Zingale LC, Pappalardo E, Folcioni A, Agostoni A. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore). 2003 Jul;82(4):274-81. DOI: 10.1097/01.md.0000085055.63483.09

91. Markovic SN, Inwards DJ, Frigas EA, Phyllyk RP. Acquired C1 esterase inhibitor deficiency. Ann Intern Med. 2000 Jan;132(2):144-50.

92. Gaur S, Cooley J, Aish L, Weinstein R. Lymphoma-associated paraneoplastic angioedema with normal C1-inhibitor activity: does danazol work? Am J Hematol. 2004 Nov;77(3):296-8. DOI: 10.1002/ajh.20195

93. Bas M, Greve J, Stelter K, Bier H, Stark T, Hoffmann TK, Kojda G. Therapeutic efficacy of icatiban in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med. 2010 Sep;56(3):278-82. DOI: 10.1016/j.annemergmed.2010.03.032

94. Bas M, Greve J, Stelter K, Havel M, Strassen U, Rotter N, Veit J, Schossow B, Hapfelmeier A, Kehl V, Kojda G, Hoffmann TK. A randomized trial of icatiban in ACE-inhibitor-induced angioedema. N Engl J Med. 2015 Jan;372(5):418-25. DOI: 10.1056/NEJMoa1312524

95. Greve J, Bas M, Hoffmann TK, Schuler PI, Weller P, Kojda G, Strassen U. Effect of C1-Esterase inhibitor in angiotensin-converting enzyme inhibitor-induced angioedema. Laryngoscope. 2015 Jun;125(6):E198-202. DOI: 10.1002/lary.25113

96. Rasmussen ER, Bygum A. ACE-inhibitor induced angio-oedema treated with complement C1-inhibitor concentrate. BMJ Case Rep. 2013 Oct 4;2013: pii: bcr20130200652. DOI: 10.1136/bcr-2013-0200652

97. Lipski SM, Casimir G, Vanlommel M, Jeanmaire M, Dolhen P. Angiotensin-converting enzyme inhibitors-induced angioedema treated by C1 esterase inhibitor concentrate (Berner®): about one case and review of the therapeutic arsenal. Clin Case Rep. 2015 Feb;3(2):126-30. DOI: 10.1002/ccr3.171

98. Bagnasco M, Altrinetti V, Pesce G, Caputo M, Mistrello G, Falagiani P, Canonica GW, Passalacqua G. Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol. 2005 Nov;138(3):197-202. DOI: 10.1159/000088719

99. Allam JP, Würtzen PA, Reinartz M, Winter J, Vitala S, Chen KW, Valenta R, Wenghoefer M, Appel T, Gros E, Niederhagen B, Bieber T, Lund K, Novak N. Ph p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, enhances their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties. J Allergy Clin Immunol. 2010 Sep;126(3):638-45.e1. DOI: 10.1016/j.jaci.2010.04.039

100. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2007 Apr;119(4):780-91. DOI: 10.1016/j.jaci.2007.01.022

101. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LC, Staple SQ, Aalberse RC, Till SJ, Durham SR. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG4 activity. J Immunol. 2004 Mar;172(5):3252-9.

102. Takhar P, Smurthwaite L, Coker HA, Fear DJ, Banfield GK, Carr VA, Durham SR, Gould HJ. Allergen drives class switching to IgG in the nasal mucosa in allergic rhinitis. J Immunol. 2005 Apr;174(8):5024-32.
103. Reisinger J, Horak F, Pauli G, van Hage M, Cromwell O, König F, Valenta R, Niederberger V. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol. 2005 Aug;116(2):347-54. DOI: 10.1016/j.jaci.2005.04.003

104. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, Thunberg S, Denz G, Valenta R, Fiebig H, Kegel C, Disch R, Schmidt-Weber CB, Blaser K, Akdis CA. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med. 2004 Jun;199(11):1567-75. DOI: 10.1084/jem.20032058

105. James LK, Durham SR. Update on mechanismsof allergen injection immunotherapy. Clin Exp Allergy. 2008 Jul;38(7):1074-88. DOI: 10.1111/j.1365-2222.2008.02976.x

106. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998 Oct;102(4 Pt 1):558-62.

107. Böcking C, Renz H, Pfefferle PI. Prävalenz und sozioökonomische Bedeutung von Allergien in Deutschland [Prevalence and socio-economic relevance of allergies in Germany]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Mar;55(3):303-7. DOI: 10.1007/s00103-011-1427-6

111. Schädlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoconomics. 2000 Jan;17(1):37-52.

112. Westerhout KY, Verheggen BG, Schneider CH, Augustin M. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. J Med Econ. 2012;15(5):906-17. DOI: 10.3111/13696998.2012.688904

113. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998 Oct;102(4 Pt 1):558-62.

114. Burchardt C. Comparison of solutions for sublingual immunotherapy. Int Arch Allergy Immunol. 2007;142(1):89-90. DOI: 10.1159/000090603

115. Schädlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoconomics. 2000 Jan;17(1):37-52.